Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Timothy Michael Pawlik

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7994-9870; OpenAlex author ID A5058146274. Sources: OpenAlex.

Their work

Papers
120 (first author 5, last author 55)
Trials
0
Grants
0
Labs led
2
Collaborators
226
Papers, trials and grants by year

2011: 4 papers · 2012: 7 papers · 2013: 7 papers · 2014: 3 papers · 2015: 7 papers · 2016: 4 papers · 2017: 5 papers · 2018: 7 papers · 2019: 7 papers · 2020: 6 papers · 2021: 9 papers · 2022: 15 papers · 2023: 10 papers · 2024: 5 papers · 2025: 11 papers · 2026: 13 papers

Papers 50 of 120

  1. Time to Treatment Initiation and Risk of Metastatic Progression in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/jso.70435↗
  2. Radiomics for early detection of pancreatic cancer: a systematic review and meta-analysis. Last author DOI 10.1016/j.gassur.2026.102374↗
  3. Geospatial treatment patterns for pancreatic ductal adenocarcinoma across United States health service areas. Last author DOI 10.1016/j.gassur.2026.102379↗
  4. Survival by treatment recommendation and treatment receipt among older adults with localized pancreatic cancer. Last author DOI 10.1016/j.gassur.2026.102423↗
  5. Early postoperative carbohydrate antigen 19-9 normalization drives prognosis after pancreatic ductal adenocarcinoma resection. Last author DOI 10.1016/j.gassur.2026.102459↗
  6. Fragmented Care for Pancreatic Cancer Patients at a High-Volume Surgical Center. Co-author DOI 10.1016/j.jss.2026.03.035↗
  7. Pancreatic Cancer. Co-author DOI 10.1016/j.soc.2025.05.007↗
  8. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Co-author DOI 10.1093/jnci/djag235↗
  9. Localized Pancreatic Cancer among Military Beneficiaries: A National Cancer Database Analysis. Last author DOI 10.1093/milmed/usaf465↗
  10. Association of Cancer Center Designation with Multimodality Treatment, Perioperative Outcomes, and Survival among Older Adults with Pancreatic Ductal Adenocarc… Last author DOI 10.1245/s10434-026-20337-5↗
  11. ASO Visual Abstract: Association of Cancer Center Designation with Multimodality Treatment, Perioperative Outcomes, and Survival Among Older Adults with Pancre… Last author DOI 10.1245/s10434-026-20394-w↗
  12. ASO Author Reflections: Not All Cancer Center Designations Confer the Same Advantage in Pancreatic Cancer Care. First author DOI 10.1245/s10434-026-20441-6↗
  13. Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy: A case series and analysis of the National Cancer Databas… Co-author DOI 10.14701/ahbps.25-209↗
  14. Variation in lymph node assessment after pancreatic cancer resection: Patient, surgeon, pathologist, or hospital? Last author DOI 10.1016/j.amjsurg.2024.116067↗
  15. Value of radiomics features extracted from baseline computed tomography images in predicting overall survival in patients with nonsurgical pancreatic ductal ad… Co-author DOI 10.1016/j.gassur.2024.101882↗
  16. Distribution of pancreatic cancer surgery centers and spatial access to care. Last author DOI 10.1016/j.gassur.2025.102186↗
  17. Hospital admission during neoadjuvant therapy for pancreatic ductal adenocarcinoma: prevalence, predictors, and prognosis. Co-author DOI 10.1016/j.hpb.2025.08.015↗
  18. Phase 1 Study of Adjuvant Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Transduced Pancreatic Tumor Cell Vaccine, Low-Dose Cyclophosphamide, and … Co-author DOI 10.1016/j.ijrobp.2024.10.039↗
  19. Long-term lorazepam use may be associated with worse long-term outcomes among patients with pancreatic adenocarcinoma. Last author DOI 10.1016/j.surg.2024.08.027↗
  20. Response to letter to the editor on "Long-term lorazepam use may be associated with worse long-term outcomes among patients with pancreatic adenocarcinoma". First author DOI 10.1016/j.surg.2024.10.006↗
  21. Textbook Neoadjuvant Experience: Defining a Novel Composite Outcomes Measure for Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy. Co-author DOI 10.1097/xcs.0000000000001277↗
  22. Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights. Co-author DOI 10.3389/fonc.2025.1544928↗
  23. Impact of Frailty on the Outcomes of Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy. Co-author DOI 10.3390/cancers17244030↗
  24. Quality Score Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Trends, Racial Disparities, and Impact on Outcomes. Last author DOI 10.6004/jnccn.2024.7089↗
  25. Evaluating the caregiver experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.27558↗
  26. Association between social determinants of health and delayed postoperative adjuvant therapy among patients undergoing resection of pancreatic cancer. Last author DOI 10.1002/jso.27571↗
  27. Association between quality metric adherence and overall survival among patients undergoing resection of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.surg.2024.04.043↗
  28. Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review. First author DOI 10.31083/j.fbl2903101↗
  29. Updates in Immunotherapy for Pancreatic Cancer. First author DOI 10.3390/jcm13216419↗
  30. Impact of early vs late palliative care referrals on healthcare utilization in patients with pancreatic cancer. Co-author DOI 10.1007/s00432-023-05113-2↗
  31. Pancreatic Cancer: Genetic Conditions and Epigenetic Alterations. Last author DOI 10.1007/s11605-022-05553-0↗
  32. Association between the Environmental Quality Index and Textbook Outcomes Among Medicare Beneficiaries Undergoing Surgery for Early-Stage Pancreatic Adenocarci… Last author DOI 10.1007/s11605-023-05757-y↗
  33. Evaluating the Quality of Online Information Regarding Neoadjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1007/s12029-022-00879-z↗
  34. Utilization of Palliative and Hospice Care Among Pancreatic Cancer Patients at an Academic Center. Co-author DOI 10.1016/j.jss.2023.03.014↗
  35. Association of County-level Upward Economic Mobility with Stage at Diagnosis and Receipt of Treatment Among Patients Diagnosed with Pancreatic Adenocarcinoma. Last author DOI 10.1097/sla.0000000000005238↗
  36. Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Serving versus Non-Minority-Serving Hospitals. Last author DOI 10.1245/s10434-023-13230-y↗
  37. ASO Author Reflections: Disparities in NCCN Guideline-Compliant Care for Patients with Early-Stage Pancreatic Adenocarcinoma at Minority-Serving Versus Non-min… Last author DOI 10.1245/s10434-023-13260-6↗
  38. Quality of ChatGPT Responses to Questions Related to Pancreatic Cancer and its Surgical Care. Last author DOI 10.1245/s10434-023-13777-w↗
  39. The Impact of Medicaid Expansion on Early-Stage Pancreatic Adenocarcinoma at High- Versus Low-Volume Facilities. Last author DOI 10.1245/s10434-023-13810-y↗
  40. Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.26706↗
  41. Implications of intensive care unit admissions among medicare beneficiaries following resection of pancreatic cancer. Last author DOI 10.1002/jso.26710↗
  42. Rates and Outcomes of Aborted Cancer Surgery among Older Patients with Pancreatic Cancer: a SEER-Medicare Study. Last author DOI 10.1007/s11605-022-05289-x↗
  43. Comparing Minimally Invasive and Open Pancreaticoduodenectomy for the Treatment of Pancreatic Cancer: a Win Ratio Analysis. Last author DOI 10.1007/s11605-022-05380-3↗
  44. Patterns of health care utilization among Medicare beneficiaries diagnosed with pancreatic adenocarcinoma. Last author DOI 10.1016/j.amjsurg.2021.10.027↗
  45. Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2021.10.010↗
  46. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled… Co-author DOI 10.1016/j.prro.2022.02.009↗
  47. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database. Co-author DOI 10.1016/j.surg.2021.12.029↗
  48. Pancreatic ductal adenocarcinoma: Emerging therapeutic strategies. Last author DOI 10.1016/j.suronc.2022.101803↗
  49. Gene signature and connectivity mapping to assist with drug prediction for pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.suronc.2022.101849↗
  50. Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis. Co-author DOI 10.1093/bjs/znac354↗

Closest collaborators

The 25 strongest of 226 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jordan M. Cloyd · 33 shared papers, 2019–2026 · strength 5.92
  2. Aslam M. Ejaz · 30 shared papers, 2015–2026 · strength 4.78
  3. Mary E. Dillhoff · 26 shared papers, 2017–2026 · strength 4.12
  4. Diamantis I. Tsilimigras · 16 shared papers, 2019–2025 · strength 3.04
  5. Meher Angez · 6 shared papers, 2026 · strength 2.31
  6. J. Madison Hyer · 12 shared papers, 2019–2023 · strength 1.85
  7. Allan Tsung · 12 shared papers, 2019–2022 · strength 1.56
  8. Joseph M. Herman · 33 shared papers, 2011–2025 · strength 1.52
  9. Daniel A. Laheru · 22 shared papers, 2011–2025 · strength 1.33
  10. Muhammad Musaab Munir · 6 shared papers, 2023–2025 · strength 1.27
  11. Anne M. Noonan · 6 shared papers, 2019–2026 · strength 1.15
  12. Henrique Araujo Lima · 5 shared papers, 2023 · strength 1.08
  13. Zorays Moazzam · 5 shared papers, 2023 · strength 1.08
  14. Adrián Díaz · 5 shared papers, 2020–2025 · strength 1.03
  15. Rabia Bega · 3 shared papers, 2026 · strength 1.03
  16. Yutaka Endo · 5 shared papers, 2023–2024 · strength 0.97
  17. Abdulaziz Elemosho · 3 shared papers, 2026 · strength 0.94
  18. Ashish Manne · 4 shared papers, 2025–2026 · strength 0.93
  19. Zachary J. Brown · 5 shared papers, 2022–2023 · strength 0.88
  20. Christopher Lee Wolfgang · 25 shared papers, 2011–2018 · strength 0.87
  21. Alessandro Paro · 4 shared papers, 2022–2025 · strength 0.83
  22. Samantha M. Ruff · 3 shared papers, 2023–2024 · strength 0.82
  23. Anghela Z. Paredes · 7 shared papers, 2018–2021 · strength 0.79
  24. Djhenne M. Dalmacy · 4 shared papers, 2022–2023 · strength 0.78
  25. Robert Connor Chick · 2 shared papers, 2024–2026 · strength 0.76

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.